DigestRedComo funciona
Red
/
Empresas
F.
No verificado

F. Hoffmann-La Roche Ltd

Sobre qué escribimos

Anuncios brevesFarmacéuticaPublicidad/Marketing/Medios de comunicación/Comunicación

160 Comunicados de prensa

Ver todos los comunicados de prensa
22/09/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
22/09/2026
Farmacéutica
Anuncios breves
Change in Roche’s Board of Directors
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
21/09/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
21/09/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
18/09/2026
Farmacéutica
Anuncios breves
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
17/09/2026
Farmacéutica
Anuncios breves
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
16/09/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
12/09/2026
Farmacéutica
Anuncios breves
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
09/09/2026
Farmacéutica
Anuncios breves
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
28/08/2026
Farmacéutica
Anuncios breves
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0